ReCor Medical Reports 100% Responder Rate at One-Year Follow-up in Clinical Trial of Its Ultrasound-Based PARADISE™ Renal Denervation System for Treating Resistant Hypertension, a Major Risk Factor for Cardiovascular Disease

Published: Nov 05, 2012

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCor Medical reported one-year follow-up data on patients who have been treated via renal denervation for their resistant hypertension with the Company’s PARADISE® System—the only CE-marked system for renal denervation that is based on ultrasound, not radiofrequency, energy. The data were presented at TCT 2012 from the podium by Peter Fitzgerald, M.D., Ph.D., Associate Professor of Medicine (Cardiology), Associate Professor of Electrical Engineering (by courtesy), and Co-Director of the Center for Research in Cardiovascular Interventions at Stanford University School of Medicine. Additionally, Dr. Fitzgerald serves as Director of Core Cardiovascular Analysis Lab at Stanford.

Back to news